Tarsus Pharmaceuticals Inc - Asset Resilience Ratio
Tarsus Pharmaceuticals Inc (TARS) has an Asset Resilience Ratio of 40.10% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Tarsus Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Tarsus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see TARS current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Tarsus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore TARS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $245.09 Million | 40.1% |
| Total Liquid Assets | $245.09 Million | 40.10% |
Asset Resilience Insights
- Very High Liquidity: Tarsus Pharmaceuticals Inc maintains exceptional liquid asset reserves at 40.10% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tarsus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Tarsus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Tarsus Pharmaceuticals Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Tarsus Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.56% | $233.63 Million | $562.16 Million | -10.58pp |
| 2024-12-31 | 52.14% | $196.56 Million | $376.99 Million | +51.20pp |
| 2023-12-31 | 0.94% | $2.50 Million | $265.49 Million | -62.86pp |
| 2022-12-31 | 63.80% | $145.37 Million | $227.86 Million | +63.53pp |
| 2021-12-31 | 0.27% | $483.00K | $178.91 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $171.97 Million | -- |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as we… Read more